PubRank

Catherine Sautès-Fridman

Author PubWeight™ 72.76‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012 10.90
2 Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002 3.17
3 Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010 2.02
4 Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011 1.91
5 Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 1.88
6 A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2005 1.86
7 Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012 1.78
8 Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 2011 1.63
9 Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 2013 1.54
10 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012 1.51
11 Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep 2012 1.45
12 Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013 1.41
13 Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med 2014 1.39
14 Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology 2013 1.36
15 Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2013 1.35
16 Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012 1.34
17 CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2011 1.34
18 Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013 1.33
19 Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012 1.33
20 Immune infiltration in human cancer: prognostic significance and disease control. Curr Top Microbiol Immunol 2011 1.32
21 Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology 2013 1.31
22 Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012 1.30
23 Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012 1.18
24 Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012 1.17
25 The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort. Chest 2014 1.13
26 Fc gamma receptors. Immunol Lett 2004 1.09
27 Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. PLoS One 2013 1.06
28 Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood 2002 1.05
29 The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. Am J Respir Crit Care Med 2015 1.02
30 Murine models of B-cell lymphomas: promising tools for designing cancer therapies. Adv Hematol 2012 1.01
31 The immune microenvironment of human tumors: general significance and clinical impact. Cancer Microenviron 2012 0.98
32 Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2010 0.95
33 The immune microenvironment: a major player in human cancers. Int Arch Allergy Immunol 2014 0.93
34 Impaired th1/tc1 cytokine production of tumor-infiltrating lymphocytes in a model of primary intraocular B-cell lymphoma. Invest Ophthalmol Vis Sci 2007 0.93
35 Tumor microenvironment in NSCLC suppresses NK cells function. Oncoimmunology 2012 0.91
36 Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J Immunol 2012 0.90
37 Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. Dermatol Res Pract 2010 0.90
38 Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel 2007 0.88
39 Characterization of immune functions in TRAF4-deficient mice. Immunology 2008 0.87
40 Selective expression of inhibitory Fcgamma receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response. Int J Cancer 2008 0.86
41 Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma. PLoS One 2011 0.85
42 Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol 2013 0.84
43 Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunol Immunother 2014 0.84
44 Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas. Invest Ophthalmol Vis Sci 2013 0.83
45 Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells. J Clin Invest 2002 0.82
46 The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Arch 2015 0.80
47 Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. J Exp Clin Cancer Res 2013 0.80
48 [Human lung cancer: role of TLR7 and TLR8 in cell survival and chemoresistance]. Med Sci (Paris) 2010 0.80
49 N-glycosylation profile of recombinant human soluble Fcgamma receptor III. Glycobiology 2002 0.80
50 Animal models of intraocular lymphomas. Ophthalmic Res 2008 0.79
51 Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited. Eur J Immunol 2007 0.79
52 Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB. J Immunol 2008 0.78
53 FcgammaRIIB is differentially expressed during B cell maturation and in B-cell lymphomas. Br J Haematol 2004 0.78
54 Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Front Immunol 2012 0.78
55 The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Front Immunol 2011 0.78
56 Fc gamma receptors and cancer. Springer Semin Immunopathol 2006 0.76
57 CD4+CD25+ T cells play a complex role in the pediatric combined liver-intestinal graft acceptance. Transplantation 2010 0.75
58 Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. J Neurooncol 2014 0.75
59 [The " rendez-vous" of the European immunologists in Paris]. Med Sci (Paris) 2007 0.75
60 The 2011 Nobel Prize in Physiology or Medicine: honor, sadness and lessons. Eur J Immunol 2011 0.75
61 EFIS-EJI supported events: courses, schools, symposia and meetings with a European flavour. Eur J Immunol 2011 0.75